Compare SCKT & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCKT | SNGX |
|---|---|---|
| Founded | 1992 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.6M |
| IPO Year | 1996 | 2006 |
| Metric | SCKT | SNGX |
|---|---|---|
| Price | $0.37 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.0M | 107.6K |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,078,332.00 | $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $0.32 |
| 52 Week High | $2.79 | $3.39 |
| Indicator | SCKT | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 40.08 |
| Support Level | N/A | $0.37 |
| Resistance Level | $0.97 | $0.82 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 16.09 | 94.70 |
Socket Mobile Inc is a producer of data capture products. The company's products are integrated into mobile applications used in mobile point of sale (mPOS), commercial services (field workers), asset tracking, manufacturing process and quality control, transportation and logistics (goods tracking and movement), event management (ticketing, entry, access control, and identification), medical and education. The company offers barcode scanning products for both one-dimensional, including imager and laser, and two-dimensional barcode scanning in standard and durable cases. The company's geographical segments are the United States, Europe, Asia and Rest of the world, of which the majority of the revenue is generated from the United States.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).